ArticlePloS one2026
Interpretable machine learning for chronic kidney disease prediction: Insights from SHAP and LIME analyses.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic kidney disease (CKD) is a progressive condition requiring early detection for optimal patient outcomes. This study developed an interpretable machine learning framework using XGBoost with SHapley Additive exPlanations (SHAP) and Local Interpretable Model-agnostic Explanations (LIME) for transparent CKD prediction. We evaluated the approach on two datasets: UAE Tawam Hospital data (n = 491) and UCI CKD data (n = 400). XGBoost with SMOTE optimization achieved 88.4% accuracy (AUC = 0.904) on the hospital dataset and 94.6% accuracy (AUC = 0.948) on the UCI dataset after Rigorous overfitting prevention through conservative hyperparameter ranges and performance monitoring ensured clinical credibility. SHAP analysis identified clinically relevant predictors: eGFRBaseline, HbA1c, and CholesterolBaseline for the hospital cohort, and specific gravity, hemoglobin, and serum creatinine for the UCI cohort. LIME provided complementary patient-level explanations that validated global SHAP patterns. The convergence between global and local interpretability methods confirms model reliability across diverse clinical contexts. This framework addresses the transparency barrier to machine learning adoption in healthcare while maintaining clinically realistic performance levels. The approach provides a foundation for integrating interpretable artificial intelligence into CKD screening and management workflows.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.